BIOS health

BIOS Health Inc.Founded in 2015 in Cambridge, UK, BIOS Health Inc. specializes in neural technology, particularly in reading and writing neural data. The company was co-founded by Emil Hewage and Oliver Armitage.BIOS Health specializes in developing advanced neural interfaces and artificial intelligence solutions designed to read and write neural data, facilitating real-time insights into the nervous system’s functionality. Its core offerings encompass a proprietary neural interface and AI platform that enable the creation of neural digital therapies, which leverage real-time feedback from the nervous system to enhance the precision of pharmaceutical treatments. This innovative technology aims to address a multitude of conditions, particularly those linked to cardiovascular diseases, by providing personalized neural therapies that improve patient outcomes.The revenue structure of BIOS Health is driven by partnerships and collaborations that focus on the co-development of neural digital therapies. The company engages in long-term partnerships with pharmaceutical companies and healthcare organizations, facilitating access to their Neural Dosing Platform, which personalizes neural therapies. These transactions are structured around collaborative agreements, where partners benefit from tailored solutions informed by high-quality neural recordings and AI capabilities. While specific pricing plans for individual products or services are not disclosed, the company’s innovative approach suggests a value-based pricing model that aligns with the effectiveness of its therapies and the insights provided by its technology.In June 2023, BIOS Health Inc. The company is focused on launching new products designed to enhance its neural therapies and plans to expand into new markets in North America and Europe by the end of 2024.

1. Seed

   Dec 4, 2018

   Amount

   $4.5M

   Investors

   Locked

2. Seed

   Mar 20, 2017

   Amount

   Undisclosed

   Investors

   Locked